相关实验视频
Updated: Jan 14, 2026

08:47
Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
48.7K
免疫检查点抑制剂相关的无菌性脑膜炎:使用FDA不良事件报告系统 (2011-2024) 进行的一项药监测研究
Hui Guo1, Yuzhu Pang2, Qian Guo3
1Department of Pharmacy, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.
Frontiers in immunology
|October 20, 2025
概括
免疫检查点抑制剂 (ICI) 可以导致无菌性脑膜炎 (AM),这是一个严重的副作用. 含有ipilimumab的疗法显示风险最高,强调了癌症患者早期神经监测的必要性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 免疫检查点抑制剂 (ICI) 是关键的癌症疗法,但可能导致与免疫相关的不良事件 (irAEs).
- 麻醉性脑膜炎 (AM) 是一种与ICI相关的严重神经性脑膜炎,对治疗方案特异性风险的实际数据有限.
研究的目的:
- 分析不同ICI疗法中的无菌性脑膜炎报告模式和安全信号.
- 识别特定的ICI组合或具有更高风险引起AM的药物.
主要方法:
- 利用FDA不良事件报告系统 (FAERS) 从2011年1月到2024年12月的数据.
- 对患者人口统计,临床特征和时间趋势进行描述性分析.
- 使用不成比例分析 (ROR,PRR,BCPNN,MGPS) 来检测与各种ICI相关的AM安全信号.
主要成果:
- 确定了498份ICI相关的AM报告;单疗法是最常见的 (78.7%).
- 主要药物包括pembrolizumab,ipilimumab/nivolumab,nivolumab和atezolizumab. 这三种药物是最常见的药物.
- 伊皮利穆马布/尼沃卢马布 (ROR 5.71) 和伊皮利穆马布单一治疗 (ROR 4.21) 显示出明显的AM风险信号;抗PD-1药物具有中度的关联 (ROR 2.55).
- 患者年龄较大 (中位数为64岁),98%符合严重不良事件标准,住院常见 (45.8%);症状发作迅速 (中位数为34天).
结论:
- 与ICI相关的AM是一个重大的安全问题,特别是在含有伊皮利姆巴的疗法中.
- 在ICI治疗的早期,AM症状的迅速发作需要警的神经监测.
- 这些发现支持将这些风险纳入临床方案,并需要进一步的机制研究.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Therapeutic Drug Monitoring: Overview and Classification
306
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
306
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
232
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
232
FDA Approved Drugs: Changes to Approved Drugs
240
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
240

